
newsSep 12, 20251:15pending
Pharma and Biotech Daily: Stay Informed, Stay Ahead
About this episode
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Capsida has reported a patient death in a gene therapy trial for epilepsy, but the exact cause of death has not been disclosed. The patient had received the gene therapy cap-002. ## The FDA is looking to streamline the development of non-opioid painkillers, while Avidity has seen functional improvements in their DMD therapy. ## The White House is reportedly considering restrictions on Chinese licensing deals in the pharmaceutical industry. ## Lilly is seeking individuals willing to challenge the status quo of medicine. ## Merck has abandoned a $1.3 billion R&D center in London, resulting in layoffs. Novo has cut 9,000 employees, and New York City's life sciences scene is growing. Thank you for tuning in to today's episode of Pharma and Biotech daily. Stay informed and have a great day!
Get every episode summarized
Each time Pharma and BioTech Daily publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Pharma and BioTech Daily

Moderna's $1B mRNA Cancer Vaccine Boosts Personalized Meds | Pharma and Biotech...
Pharma and BioTech Daily
Sep 14, 20265:55completed

FDA Expands Bayer's Hyrnuo Approval | Pharma and Biotech Daily
Pharma and BioTech Daily
Sep 11, 20264:55completed

Sandoz Invests $2.5B in Biosimilars Network | Pharma and Biotech Daily
Pharma and BioTech Daily
Sep 10, 20264:42completed

AstraZeneca's $116M FDA Win: New Breast Cancer Drug | Pharma and Biotech Daily
Pharma and BioTech Daily
Sep 9, 20265:06completed